Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China

Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China

Abstract Objectives Juvenile dermatomyositis (JDM) is a chronic autoimmune disease. Some patients remain in an active state even though they were administrated with a combination of corticosteroid and methotrexate. Existing research has suggested that interferon and Janus kinase played an important...

Full description

Bibliographic Details
Main Authors: Junmei Zhang, Li Sun, XinWei Shi, Shipeng Li, Cuihua Liu, Xiaoqing Li, Meiping Lu, Jianghong Deng, Xiaohua Tan, Wanzhen Guan, Guomin Li, Xinran Wen, Ping Liu, Caifeng Li
Format: Article
Language:English
Published: BMC 2023-10-01
Series:Arthritis Research & Therapy
Subjects:
Juvenile dermatomyositis
Tofacitinib
Biologic therapy
Janus kinase inhibitor
Refractory
Online Access:https://doi.org/10.1186/s13075-023-03170-z

Internet

https://doi.org/10.1186/s13075-023-03170-z

Similar Items